Chronic, excessive neuroinflammation is a key feature of neurodegenerative diseases such
as Alzheimer's disease (AD) and Parkinson's disease (PD). However, neuroinflammatory …

Neurodegenerative diseases (NDDs) are identified by the progressive deterioration of
neurons and a subsequent decline in cognitive function, creating an enormous burden on …

Objective Evaluating the efficacy of 3, 6'‐dithioPomalidomide in 5xFAD Alzheimer's disease
(AD) mice to test the hypothesis that neuroinflammation is directly involved in the …

Mild cognitive impairment (MCI) is a common trait of Parkinson's disease (PD), often
associated with early motor deficits, eventually evolving to PD with dementia in later disease …

The immunomodulatory imide drug (IMiD) class, which includes the founding drug member
thalidomide and later generation drugs, lenalidomide and pomalidomide, has dramatically …

The “Thalidomide tragedy” is a landmark in the history of the pharmaceutical industry.
Despite limited clinical trials, there is a continuous effort to investigate thalidomide as a drug …

Neuropsychiatric disorders are multifaceted syndromes with confounding neurological
explanations. It includes anxiety, depression, autism spectrum disorder, attention deficit …

Traumatic brain injury (TBI) is a leading cause of disability and mortality worldwide. It can
instigate immediate cell death, followed by a time-dependent secondary injury that results …

Current antiepileptic strategies aim to normalize the interaction of the excitatory and
inhibitory systems, which is ineffective in treating patients with drug-resistant epilepsy …

Traumatic brain injury (TBI) is a major risk factor for several neurodegenerative disorders,
including Parkinson's disease (PD) and Alzheimer's disease (AD). Neuroinflammation is a …